CD19 Antibody (1062909) [Alexa Fluor® 488]

• Reactivity: Hu
• Clone: 1062909
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 488

CD19 Antibody (1062909) [Alexa Fluor® 488] Summary

• Immunogen: Chinese Hamster Ovary cell line, CHO-derived human CD19
  Met1-Lys291
  Accession # P15391
• Specificity: Detects recombinant human CD19 protein in Direct ELISA.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CD19 Antibody (1062909) [Alexa Fluor® 488]

• B4
• B-lymphocyte antigen CD19
• B-lymphocyte surface antigen B4
• CD19 antigen
• CD19 molecule
• CD19
• CVID3
• Differentiation antigen CD19
• Leu-12
• MGC12802
• T-cell surface antigen Leu-12

Background

CD19, also known as B4, is a transmembrane glycoprotein of the immunoglobulin superfamily that plays a central role in B cell activation and humoral immune responses (1, 2). CD19 consists of an extracellular domain (ECD) with two C2-type Ig-like domains, a transmembrane segment, and a cytoplasmic domain with nine tyrosine residues, 3 of which are critical for function (1, 2). Within the mature ECD, human CD19 shares 57% amino acid sequence identity with mouse and rat CD19. CD19 is expressed throughout B cell development from pre‑B cells through mature B cells, and it is commonly used as a B cell lineage marker (1, 2). It is required for the responsiveness of mature B cell to antigen stimulation, germinal center development, and antibody affinity maturation (1, 2). CD19 associates with the B cell antigen receptor (BCR), CD81, CD38, CD21, CD22, and IFITM1/CD225/Leu-13 (1, 3). These associations enable CD19 to amplify B cell signaling and reduce the threshold for antigen stimulation through the BCR (1, 3). CD19 polymorphisms and up-regulation can lead to the development of autoimmunity by promoting autoantibody production (2). CD19 has emerged as promising therapeutic target for hematologic cancers and solid tumors, such as leukemias and lymphomas (4, 5). Immunotherapy using a chimeric antigen receptor (CAR) targeting CD19 has emerged as promising therapeutic target for hematologic cancers and solid tumors, such as leukemias and lymphomas (4, 5). The first CD19 CAR T cell therapies have been granted FDA approval for the treatment of B cell malignancies with several more in clinical trials (6).

1. Wang, K. et al. (2012) Exp. Hematol. Oncol. 1:36.
2. Del Nargo, C.J. et al. (2005) Immunol Res. 31:229.
3. Yu, F. et al. (2010) J Neurooncol. 103:187.
4. Kochenderfer, J. et al. (2015) J. Clin. Oncol. 33:540.
5. Lee, D. et al. (2015) Lancet. 385:517.
6. Ahmad, A. et al. (2020) Int. J. Mol. Sci. 21:3906.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P15391(Human)